News

Our Healthcare News

EUSA Pharma Announces Acquisition of Global Rights to SYLVANT (siltuximab) from Janssen Sciences Ireland UC for $115 Million

Acquisition significantly boosts EUSA Pharma’s presence as a global biopharmaceutical company in oncology and rare diseases

SYLVANT is the only FDA and EMA approved treatment…  

Jul 18 2018

AxoGen Chairman and CEO Karen Zaderej Named Entrepreneur of the Year 2018 Award Winner in Florida

ALACHUA, Florida—(GLOBE NEWSWIRE)—AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerves, today announced that Ernst & Young (EY)…  

Jun 08 2018

AxoGen, Inc Announces Upsizing and Pricing of Public Offering of Common Stock

ALACHUA, Florida (GLOBE NEWSWIRE)—AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerves, announced today that it has priced…  

May 09 2018

Encore Dermatology, Inc. Announces the Launch of IMPOYZ (clobetasol propionate) Cream, 0.025%, a Newly Formulated High-Potency Topical Corticosteroid

MALVERN, Pennsylvania—Encore Dermatology Inc. announces today the availability of a new topical product, IMPOYZ Cream, indicated for the treatment of moderate to severe plaque psoriasis…  

May 01 2018

pSivida Corp. Announces Transformative Acquisition of Icon Bioscience Inc. and Growth Capital Financing with Essex Woodlands Healthcare Partners - Company will Rebrand as EyePoint Pharmaceuticals, Inc.

WATERTOWN, Massachusetts(GLOBE NEWSWIRE)—pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced the acquisition of Icon Bioscience…  

Mar 28 2018

EUSA Pharma Appoints Industry Veteran Rolf K Hoffmann to its Board of Directors

HEMEL HEMPSTEAD, England –– EUSA Pharma (EUSA), a world-class specialty pharmaceutical company focused on oncology and oncology supportive care, today announced the appointment of Rolf…  

Mar 07 2018

Cota Announces $40 Million Series C Financing to Advance Classification System

NEW YORK, NY—Cota Inc., a healthcare real-world evidence and data analytics company bridging precision medicine to population health, today announced the completion of a Series…  

Feb 21 2018

AxoGen, Inc. Announces Proposed Public Offering of Common Stock

ALACHUA, Florida—(GLOBE NEWSWIRE)—AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the repair of peripheral nerve damage, announced today that…  

Nov 15 2017

EUSA Pharma and AVEO Oncology Announce First Commercial Launch of FOTIVDA (tivozanib)

HEMEL HEMPSTEAD, England & CAMBRIDGE, Massachusetts. – – EUSA Pharma and AVEO Oncology (NASDAQ: AVEO) today announced the first commercial launch of FOTIVDA® (tivozanib) with…  

Nov 15 2017



View Legacy Fund news >